Tesamorelin 10mg, Ipamorelin 10mg + MOTS-C 10mg Research Bundle
USA Made, ≥99% Purity Per Compound
4.9 177 verified reviews- Separate retail vials: Tesamorelin 10mg; Ipamorelin 10mg; MOTS-C 10mg
- USA manufactured in a Certified GMP California and Arizona laboratory.
- ≥99% purity target per compound with independent third-party HPLC, mass spectrometry, and batch-specific COAs
For research purposes only. Not intended for human consumption, medical use, diagnosis, treatment, or prevention of disease.
Per-compound specifications
3 vialsNothing in this bundle is co-formulated. Each vial keeps its own identity, purity target, and certificate, and is specified separately below.
- CAS
- 218949-48-5
- Molecular mass
- 5,136 g/mol
- Purity target
- ≥99%
- Form
- Lyophilized Powder
- CAS
- 170851-70-4
- Molecular mass
- 711.9 g/mol
- Purity target
- ≥99%
- Form
- Lyophilized Powder
- CAS
- 1627580-64-6
- Molecular mass
- 2,174.6 g/mol
- Purity target
- ≥99%
- Form
- Lyophilized Powder
- Form
- 3 Separate Lyophilized Powders
- Purity target
- ≥99% per compound (3rd-Party HPLC Tested)
- Origin
- All Included Products: Synthesized, Formulated & Packaged in CA/AZ, USA
- Storage
- Store at -20°C (Freeze) or 2–8°C (Refrigerated) protected from light
What is the Tesamorelin 10mg, Ipamorelin 10mg + MOTS-C 10mg Research Bundle?
This three-vial research bundle combines Tesamorelin 10mg, Ipamorelin 10mg, and MOTS-C 10mg. Tesamorelin is a modified 44-amino-acid GHRH analog used to study receptor activation and downstream growth-hormone-axis signals. Ipamorelin is a modified five-residue peptide studied as a selective GHS-R1a, or ghrelin-receptor, agonist. MOTS-C is a 16-amino-acid mitochondrial-derived peptide examined in metabolic-stress, nutrient-sensing, and AMPK-related models.
Together, the set supports controlled work across GHRH-receptor, ghrelin-receptor, mitochondrial, nutrient-sensing, and AMPK-related signaling. Each retail product stays in its own lyophilized vial, so the bundle does not create a new formulation or establish a proven combined effect.
How It Works
Tesamorelin models GHRH-receptor signaling: Receptor engagement supports controlled measurement of cAMP-linked pituitary and downstream pathway markers.
Ipamorelin engages GHS-R1a: This ghrelin-receptor route provides a defined growth-hormone-secretagogue signal in experimental models.
MOTS-C connects mitochondrial and metabolic-stress research: Preclinical work examines folate-cycle changes, AICAR signaling, and downstream AMPK activation.
One certificate per vial
Independent third-party HPLC assesses each compound against its ≥99% purity target, while mass spectrometry confirms identity. For each vial, the results are documented in one combined, batch-specific COA report.
- Lot
- T522
- Reported
- 2026-04-23
- Identity (LC-MS)
- Confirmed
- Purity (HPLC-UV)
- 99.58%
- Net content
- 9.85 mg
- Appearance
- White lyophilized powder
- Lot
- IP341
- Reported
- 2026-06-01
- Identity (LC-MS)
- Confirmed
- Purity (HPLC-UV)
- 99.88%
- Net content
- 10.29 mg
- Appearance
- White lyophilized powder
- Lot
- MS431
- Reported
- 2026-06-01
- Identity (LC-MS)
- Confirmed
- Purity (HPLC-UV)
- 99.64%
- Net content
- 10.59 mg
- Appearance
- White lyophilized powder
Why Source from 321 Peptides?
Lot history 12 released lots
Every batch released under each vial in this bundle, with the figure reported for each. Vials are shipped from current stock.
| Compound | Lot | Reported | Purity | Net content | COA |
|---|---|---|---|---|---|
| Tesamorelin 10mg | TE-32025 | 2026-04-23 | 99.46% | 10.00 mg | Pending |
| T522 | 2026-04-23 | 99.58% | 9.85 mg | ||
| TE-33179 | 2026-04-08 | 99.83% | 10.02 mg | Pending | |
| TE-32602 | 2026-03-19 | 99.58% | 10.01 mg | Pending | |
| Ipamorelin 10mg | IP341 | 2026-06-01 | 99.88% | 10.29 mg | |
| IP-64086 | 2026-05-06 | 99.64% | 10.03 mg | Pending | |
| IP-63509 | 2026-04-08 | 99.52% | 10.02 mg | Pending | |
| IP-62932 | 2026-03-19 | 99.71% | 10.01 mg | Pending | |
| MOTS-C 10mg | MS431 | 2026-06-01 | 99.64% | 10.59 mg | |
| MO-57344 | 2026-05-06 | 99.46% | 10.02 mg | Pending | |
| MO-57921 | 2026-05-02 | 99.58% | 10.03 mg | Pending | |
| MO-56767 | 2026-04-08 | 99.49% | 10.01 mg | Pending |